The Top 5 Biosimilar Articles for the Week of February 21

Here are the top 5 biosimilar articles for the week of February 21, 2022.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of February 21, 2022.

Number 5: In a 50-46 vote, the Senate confirmed Robert Califf, MD, as President Biden’s FDA commissioner. The agency has been without a permanent leader for more than a year.

Number 4: A report from AHIP found 3 drugs that have multiple biosimilars available can be delivered more affordably through specialty pharmacies.

Number 3: A panel of experts detailed the current concerns regarding interchangeability designations for biosimilars in the United States and calls for regulators and policy makers to make changes to allow for easier access to biosimilars and greater adoption.

Number 2: Iceland’s national health plan required patients to switch from Humira to the Samsung Bioepis biosimilar, Imraldi, which had a different injection device and contained citrate, a chemical buffer used to maintain the medication’s stability.

Number 1: Selexis and Generium launched an omalizumab biosimilar on the Russian market; Remsima sales hit a record high for Celltrion Healthcare; Xbrane Biopharma shares long-term results for its ranibizumab biosimilar.

To read all of these articles and more, visit centerforbiosimilars.com.